Eli Lilly and Company (LLY) Shares Sold by Tocqueville Asset Management L.P.
Tocqueville Asset Management L.P. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 22.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,600 shares of the company’s stock after selling 6,578 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in Eli Lilly and were worth $1,933,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Eli Lilly and by 2,628.5% during the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after purchasing an additional 59,978,664 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Eli Lilly and by 7,093.5% during the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after purchasing an additional 9,223,251 shares during the period. Dodge & Cox raised its position in shares of Eli Lilly and by 22,094.9% during the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after purchasing an additional 5,964,955 shares during the period. Renaissance Technologies LLC raised its position in shares of Eli Lilly and by 91.1% during the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after purchasing an additional 2,714,505 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Eli Lilly and by 3.3% during the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after purchasing an additional 2,181,701 shares during the period. 76.42% of the stock is owned by institutional investors.
Eli Lilly and Company (LLY) traded up $0.58 on Monday, hitting $86.45. The company’s stock had a trading volume of 3,777,100 shares, compared to its average volume of 3,673,659. Eli Lilly and Company has a 1 year low of $67.22 and a 1 year high of $89.09. The firm has a market cap of $95,189.66, a P/E ratio of 21.14, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th were issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.41%. The ex-dividend date of this dividend was Tuesday, November 14th. Eli Lilly and’s payout ratio is 98.58%.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of Eli Lilly and stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $85.14, for a total transaction of $16,602,300.00. Following the completion of the sale, the insider now owns 123,513,247 shares of the company’s stock, valued at $10,515,917,849.58. The disclosure for this sale can be found here. Insiders sold a total of 628,588 shares of company stock valued at $53,399,536 in the last 90 days. 0.20% of the stock is owned by corporate insiders.
Several research firms recently weighed in on LLY. Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and boosted their price objective for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Piper Jaffray Companies reissued a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a research report on Thursday, August 31st. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research report on Thursday, October 26th. Jefferies Group reissued a “buy” rating and set a $89.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the stock a “sell” rating in a research report on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $90.25.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.